Independence Blue CrossMedicare Advantage · Billing Codes · Pharmacy · Pharmacy, Cardiology, Internal Medicine +1 moreMedium impact
MA08.133d, Evinacumab-dgnb (Evkeeza®)
Act
by Oct 1, 2025
Effective date
Oct 1, 2025
Identified
Jun 19, 2026
Summary
Independence Blue Cross updated Medicare Advantage policy MA08.133d on October 1, 2025, replacing the ICD-10 diagnosis code E78.01 (Familial hypercholesterolemia) with E78.010 (Homozygous familial hypercholesterolemia [HoFH]) for Evinacumab-dgnb (Evkeeza) coverage. This diagnostic code change requires billing teams to use the more specific HoFH code for all new and existing claims to ensure proper reimbursement under the medical benefit (Part B).
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
01Billing team must update all claim submission systems, superbills, and encounter templates to discontinue use of ICD-10 code E78.01 and replace it exclusively with E78.010 for Evinacumab-dgnb (Evkeeza) claims.
02Update prior authorization templates and clinical documentation guidelines to reflect the new specific code.
03Audit any pending claims using the old code E78.01 and resubmit with E78.010.
04Train providers and clinical staff on the new diagnostic code requirement.
If missed: Failure to use E78.010 may result in claim denials or delays for this rare disease indication.
Codes mentioned
J1305E78.01E78.010
Original notice
MA08.133d, Evinacumab-dgnb (Evkeeza®)
medpolicy.ibx.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.